In what can only be described as an ironic twist, the Indian Journal of Dermatology is retracting a paper that presents guidelines on plagiarism for…wait for it…
The Journal of Cosmetic and Laser Therapy has retracted a 2014 paper by a group of South Korean researchers after determining that the authors had doubled up on their publishing odds by submitting the manuscript to a competing journal.
The article was titled “A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner’s solution in melasma patients,” and it purported to find that:
This study suggests Jessner’s peel is a safe and effective method in the early course of treatment for melasma when combined with low-fluence 1064-nm Q-switched Nd:YAG laser.
The Journal of the American Academy of Dermatology has issued an expression of concern about a 2012 article reporting the experience of military burn unit treating a rare ailment called toxic epidermal necrolysis.
A Boston doctor indicted on charges of Medicare fraud in 2007 has had a paper relating to the case retracted this month.
Abdul Razzaque Ahmed was considered something of a miracle worker by his patients, treating two rare and disfiguring skin conditions called pemphigoid and pemphigus vulgaris. He used more powerful medicines than the typical course of treatment, including a drug normally used to treat cancer.
The initial indictment stated that Ahmed mixed blood samples to falsely show a “dual diagnosis” of both diseases, and prove to Medicare that they required the more rigorous (and expensive) treatment. It also alleged that he profited massively from the government pay-outs. He was convicted of obstruction in 2007; the other charges were dropped when he agreed to forfeit assets worth $2.9 million.
A group of dermatology researchers from Egypt who passed around a psoriasis paper like a bottle of sunscreen at the beach have been burned (sorry) by a journal that caught them in the act.
Acta Dermatovenerologica Alpina, Pannonica et Adriatica is retracting the 2009 article “Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt” after discovering that they were far from the first publication to print the paper.
In what may be a first, a researcher in Turkey has withdrawn a paper because the patients whose cases she described wthdrew their consent after it was published.
An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.
The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.
According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.
We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).
The Office of Research Integrity (ORI) has sanctioned an assistant professor of dermatology at Case Western Reserve University in Cleveland for plagiarizing from a grant application she was reviewing — which feels like a scientific version of insider trading — and a number of published papers.
A group of researchers from India and China has lost a 2012 article in the Biochemical Engineering Journal for lifting a figure from a previously published article from another team of investigators. Evidently, caught red-handed, they haven’t copped to the caper.